ORIC Pharmaceuticals (ORIC) 10-Q 5 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Registrant Name	ORIC PHARMACEUTICALS, INC.
Trading Symbol	ORIC
Entity Central Index Key	0001796280
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		30,837,807
Entity File Number	001-39269
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-1787157
Entity Address, Address Line One	240 E. Grand Ave
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	388-5600
Document Quarterly Report	true
Document Transition Report	false

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 62,031	$ 89,159
Marketable securities	124,579
Prepaid expenses and other current assets	2,448	840
Total current assets	189,058	89,999
Property and equipment, net	1,893	2,241
Other assets	711	1,853
Total assets	191,662	94,093
Current liabilities:
Accounts payable	1,598	152
Accrued liabilities	5,330	5,202
Total current liabilities	6,928	5,354
Deferred rent - long term	359	765
Total liabilities	7,287	6,119
Commitments and contingencies (Note 10)
Stockholders' equity (deficit):
Common stock, $0.0001 par value; 1,000,000,000 shares and 26,750,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 30,545,165 shares and 1,984,222 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	3
Additional paid-in capital	322,535	2,606
Accumulated deficit	(138,134)	(92,690)
Accumulated other comprehensive loss	(29)
Total stockholders' equity (deficit)	184,375	(90,084)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 191,662	94,093
Series A Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock		15,431
Series B Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock		53,906
Series C Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock		53,172
Series D Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock		$ 55,549

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Convertible preferred stock, authorized		20,348,788
Convertible preferred stock, issued		19,278,606
Convertible preferred stock, outstanding		19,278,606
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	26,750,000
Common stock, shares, issued	30,545,165	1,984,222
Common stock, shares, outstanding	30,545,165	1,984,222
Series A Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized	0	3,862,500
Convertible preferred stock, issued	0	3,862,500
Convertible preferred stock, outstanding	0	3,862,500
Aggregate liquidation preference	$ 0	$ 15,450
Series B Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized	0	6,750,000
Convertible preferred stock, issued		6,749,999
Convertible preferred stock, outstanding	0	6,749,999
Aggregate liquidation preference	$ 0	$ 54,000
Series C Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized	0	4,448,788
Convertible preferred stock, issued		4,448,780
Convertible preferred stock, outstanding	0	4,448,780
Aggregate liquidation preference	$ 0	$ 53,385
Series D Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized	0	5,287,500
Convertible preferred stock, issued		4,217,327
Convertible preferred stock, outstanding	0	4,217,327
Aggregate liquidation preference	$ 0	$ 55,669

STATEMENTS OF OPERATIONS AND CO

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 8,831	$ 5,632	$ 23,808	$ 15,884
Acquired in-process research and development	12,971		12,971
General and administrative	3,800	1,465	9,125	3,914
Total operating expenses	25,602	7,097	45,904	19,798
Loss from operations	(25,602)	(7,097)	(45,904)	(19,798)
Other income:
Interest income, net	10	476	276	1,054
Other income	44	72	184	215
Total other income	54	548	460	1,269
Net loss	(25,548)	(6,549)	(45,444)	(18,529)
Other comprehensive loss:
Unrealized loss on available-for-sale securities	(29)		(29)
Comprehensive loss	$ (25,577)	$ (6,549)	$ (45,473)	$ (18,529)
Net loss per share, basic and diluted	$ (0.84)	$ (3.36)	$ (2.52)	$ (9.87)
Weighted-average shares outstanding, basic and diluted	30,314,904	1,946,439	18,022,068	1,876,687

STATEMENTS OF CONVERTIBLE PREFE

STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Initial Public Offering	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Series D Convertible Preferred Stock	Common Stock	Common StockInitial Public Offering	Additional Paid-in Capital	Additional Paid-in CapitalInitial Public Offering	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning Balance at Dec. 31, 2018			$ 15,431	$ 53,906	$ 37,929
Beginning Balance (in shares) at Dec. 31, 2018			3,862,500	6,749,999	3,177,271
Beginning Balance at Dec. 31, 2018	$ (64,426)								$ 1,381		$ (65,807)
Beginning Balance (in shares) at Dec. 31, 2018							1,802,134
Issuance of preferred stock, net of issuance costs					$ 15,243
Issuance of preferred stock, net of issuance costs (in shares)					1,271,509
Exercise of common stock options and vesting of early exercised common stock options	21								21
Exercise of common stock options and vesting of early exercised common stock options (in shares)							26,159
Stock-based compensation expense	191								191
Net loss	(6,015)										(6,015)
Ending Balance at Mar. 31, 2019			$ 15,431	$ 53,906	$ 53,172
Ending Balance (in shares) at Mar. 31, 2019			3,862,500	6,749,999	4,448,780
Ending Balance at Mar. 31, 2019	(70,229)								1,593		(71,822)
Ending Balance (in shares) at Mar. 31, 2019							1,828,293
Issuance of preferred stock, net of issuance costs						$ 49,864
Issuance of preferred stock, net of issuance costs (in shares)						3,777,564
Exercise of common stock options and vesting of early exercised common stock options	59								59
Exercise of common stock options and vesting of early exercised common stock options (in shares)							111,884
Stock-based compensation expense	190								190
Net loss	(5,965)										(5,965)
Ending Balance at Jun. 30, 2019			$ 15,431	$ 53,906	$ 53,172	$ 49,864
Ending Balance (in shares) at Jun. 30, 2019			3,862,500	6,749,999	4,448,780	3,777,564
Ending Balance at Jun. 30, 2019	(75,945)								1,842		(77,787)
Ending Balance (in shares) at Jun. 30, 2019							1,940,177
Issuance of preferred stock, net of issuance costs						$ 5,685
Issuance of preferred stock, net of issuance costs (in shares)						439,763
Exercise of common stock options and vesting of early exercised common stock options	14								14
Exercise of common stock options and vesting of early exercised common stock options (in shares)							15,789
Stock-based compensation expense	271								271
Net loss	(6,549)										(6,549)
Ending Balance at Sep. 30, 2019			$ 15,431	$ 53,906	$ 53,172	$ 55,549
Ending Balance (in shares) at Sep. 30, 2019			3,862,500	6,749,999	4,448,780	4,217,327
Ending Balance at Sep. 30, 2019	$ (82,209)								2,127		(84,336)
Ending Balance (in shares) at Sep. 30, 2019							1,955,966
Beginning Balance at Dec. 31, 2019			$ 15,431	$ 53,906	$ 53,172	$ 55,549
Beginning Balance (in shares) at Dec. 31, 2019	19,278,606		3,862,500	6,749,999	4,448,780	4,217,327
Beginning Balance at Dec. 31, 2019	$ (90,084)								2,606		(92,690)
Beginning Balance (in shares) at Dec. 31, 2019	1,984,222						1,984,222
Exercise of common stock options and vesting of early exercised common stock options	$ 12								12
Exercise of common stock options and vesting of early exercised common stock options (in shares)							13,433
Stock-based compensation expense	527								527
Net loss	(8,872)										(8,872)
Ending Balance at Mar. 31, 2020			$ 15,431	$ 53,906	$ 53,172	$ 55,549
Ending Balance (in shares) at Mar. 31, 2020			3,862,500	6,749,999	4,448,780	4,217,327
Ending Balance at Mar. 31, 2020	(98,417)								3,145		(101,562)
Ending Balance (in shares) at Mar. 31, 2020							1,997,655
Exercise of common stock options and vesting of early exercised common stock options	39								39
Exercise of common stock options and vesting of early exercised common stock options (in shares)							23,200
Stock-based compensation expense	1,381								1,381
Initial public offering of common stock		$ 138,000						$ 1		$ 137,999
Initial public offering of common stock (in shares)								8,625,000
Issuance costs associated with initial public offering		$ (12,790)								$ (12,790)
Conversion to Common Stock			$ (15,431)	$ (53,906)	$ (53,172)	$ (55,549)
Conversion to Common Stock (in shares)			(3,862,500)	(6,749,999)	(4,448,780)	(4,217,327)
Conversion to Common Stock	178,058						$ 2		178,056
Conversion to Common Stock (in shares)							19,278,606
Net loss	(11,024)										(11,024)
Ending Balance at Jun. 30, 2020	195,247						$ 3		307,830		(112,586)
Ending Balance (in shares) at Jun. 30, 2020							29,924,461
Exercise of common stock options and vesting of early exercised common stock options	53								53
Exercise of common stock options and vesting of early exercised common stock options (in shares)							32,469
Stock-based compensation expense	1,681								1,681
Issuance of common stock related to acquisition	12,971								12,971
Issuance of common stock related to acquisition (in shares)							588,235
Other comprehensive loss	(29)											$ (29)
Net loss	(25,548)										(25,548)
Ending Balance (in shares) at Sep. 30, 2020			0	0	0	0
Ending Balance at Sep. 30, 2020	$ 184,375						$ 3		$ 322,535		$ (138,134)	$ (29)
Ending Balance (in shares) at Sep. 30, 2020	30,545,165						30,545,165

STATEMENTS OF CONVERTIBLE PRE_2

STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Mar. 31, 2019
Series C Convertible Preferred Stock
Preferred stock, issuance costs		$ 213
Series D Convertible Preferred Stock
Preferred stock, issuance costs	$ 121

STATEMENTS OF CASH FLOWS (Unaud

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (45,444)	$ (18,529)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	736	758
Stock-based compensation expense	3,589	652
Non-cash stock consideration, acquisition	12,971
Loss on fixed asset disposal		7
Amortization of discount on investments, net	33
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,599)	223
Accounts payable and accrued other liabilities	2,271	504
Net cash used in operating activities	(27,443)	(16,385)
Cash flows from investing activities:
Acquisitions of property and equipment	(256)	(712)
Purchases of marketable securities	(124,640)
Proceeds from notes receivable	193
Net cash used in investing activities	(124,703)	(712)
Cash flows from financing activities:
Proceeds from issuance of common stock pursuant to initial public offering, gross	138,000
Issuance costs associated with initial public offering	(12,692)
Payment of deferred financing costs	(394)
Proceeds from issuance of preferred stock		70,927
Issuance costs associated with preferred stock		(136)
Proceeds from stock option exercises	104	94
Net cash provided by financing activities	125,018	70,885
Net (decrease) increase in cash and cash equivalents	(27,128)	53,788
Cash and cash equivalents, beginning of period	89,159	42,636
Cash and cash equivalents, end of period	62,031	96,424
Supplemental disclosure of non-cash investing and financing activities:
Conversion of preferred stock to common stock	178,058
Amounts accrued for purchase of property and equipment	$ 132	11
Unpaid deferred financing costs		$ 240

Description of the Business

Description of the Business	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of the Business	1. Description of the Business ORIC Pharmaceuticals, Inc. (ORIC or the Company) is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by O vercoming R esistance I n C ancer Since inception, the Company has devoted its primary efforts to raising capital, internal research and development activities and business development efforts and has incurred significant operating losses and negative cash flows from operations. In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi, Inc. development and commercialization rights to a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations. As of September 30, 2020, the Company had an accumulated deficit of $138.1 million. Through September 30, 2020, all of the Company’s financial support has been provided primarily from the sale of convertible preferred stock and proceeds from the issuance of common stock. As the Company continues its expansion, it may seek additional financing and/or strategic investments, however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these unaudited interim financial statements. Initial Public Offering and Related Transaction On April 28, 2020, the Company completed an initial public offering (IPO) selling 8,625,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase up to 1,125,000 additional shares, at a price of $16.00 per share resulting in gross proceeds of $138.0 million. After deducting underwriting discounts and commissions and other offering expenses related to the IPO of $12.8 million, the net proceeds to the Company from the transaction were $125.2 million. In connection with the IPO, all shares of convertible preferred stock outstanding at the time of the IPO converted into 19,278,606 shares of common stock. On April 21, 2020, the Company amended its certificate of incorporation to effect a one-for- four

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP, have been omitted. The accompanying unaudited financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, the majority of the Company’s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company’s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on April 24 , 2020 under the Securities Act of 1933, as amended (the Securities Act). In the third quarter of 2020, the Company began reporting deferred offering costs within its other assets on its balance sheets. To conform to current presentation, the Company included $1.3 million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company’s total assets, net loss or stockholders’ equity (deficit) as previously reported. Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure. The carrying amounts of cash, cash equivalents and marketable securities, prepaid expenses, accounts payable and accrued other liabilities are reasonable estimates of their fair value because of the short maturity of these items. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of 90 days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper. Marketable Securities Investments with maturities at the date of acquisition of more than 90 days are considered marketable securities. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management’s strategies. The Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. Marketable Research and Development Expenses and Accrued Research and Development Expenses The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. License Fees Acquisitions of technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. Deferred Offering Costs The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator Net loss $ (25,548 ) $ (6,549 ) $ (45,444 ) $ (18,529 ) Denominator Weighted average shares outstanding used in computing net loss per share, basic and diluted 30,314,904 1,946,439 18,022,068 1,876,687 Net loss per share, basic and diluted $ (0.84 ) $ (3.36 ) $ (2.52 ) $ (9.87 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of September 30, 2020 2019 Options to purchase common stock 3,959,693 2,251,594 Convertible preferred stock — 19,278,606 Total 3,959,693 21,530,200 Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. In December 2019, the FASB issued ASU No 2019-12 , Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 which had no material effect on the Company’s current financial position, results of operations or financial statement disclosures. New Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Codification Improvements to Topic 842, Leases Leases (Topic 842): Targeted Improvements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses ( Topic 326 ) (ASC 326): Measurement of Credit Losses on Financial Instruments , which introduced the expected credit losses methodology for the

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2020
License Agreements [Abstract]
License Agreements	3. License Agreements On August 3, 2020, the Company entered into a license agreement (Mirati License Agreement) with Mirati Therapeutics, Inc (Mirati). Under the Mirati License Agreement, Mirati granted the Company a worldwide, exclusive, sublicensable, royalty-free license under Mirati’s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compounds. Under the Mirati License Agreement, the Company is wholly responsible for development and commercialization of licensed products. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in certain major markets. Unless earlier terminated, the Mirati License Agreement will continue in effect on a country-by-country and licensed product-by-licensed product basis until the later of (a) the expiration of the last valid claim of a licensed patent covering such licensed product in such country or (b) ten years after the first commercial sale of such licensed product in such country. Following the expiration of the Mirati License Agreement, the Company will retain its licenses under the intellectual property Mirati licensed to it on a royalty-free basis. ORIC and Mirati may each terminate the Mirati License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Mirati may terminate the agreement if the Company challenges any of the patent rights licensed to us by Mirati or it discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Mirati License Agreement without cause by providing prior notice to Mirati. The Company’s financial obligations under the Mirati License Agreement was comprised of an upfront payment of 588,235 shares of ORIC common stock, valued at approximately $13.0 million based upon the closing price of the Company’s common stock on the acquisition date. The number of shares was based on a price of $34.00 per share, representing a premium of 10% to the 60-day trailing volume-weighted average trading price of the Company’s common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering. eighteen-month is subject to certain transfer restrictions, and the parties agreed to negotiate and enter into a registration rights agreement, with respect to the shares. The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a single identifiable asset. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge at the closing of the transaction for the full $13.0 million value assigned to the shares issued. This non-cash charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2020. On October 19, 2020, the Company entered into a license agreement with Voronoi, Inc. (Voronoi). See Note 11 for further discussion.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, net Property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Lab equipment $ 4,088 $ 3,748 Leasehold improvements 1,710 1,710 Computer hardware and software 206 158 Furniture and fixtures 140 140 Total property and equipment, gross 6,144 5,756 Less accumulated depreciation (4,251 ) (3,515 ) Total property and equipment, net $ 1,893 $ 2,241

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Accrued Liabilities Current [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrued compensation $ 2,229 $ 1,883 Accrued clinical development costs 1,391 484 Accrued professional fees 657 338 Deferred rent - short-term 535 495 Accrued manufacturing costs 278 479 Other accruals 240 279 Accrued deferred financing costs — 1,244 Total accrued liabilities $ 5,330 $ 5,202

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Marketable Securities	6. Marketable Securities The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company’s investment policy, it has invested funds in marketable securities as of September 30, 2020. The Company had no marketable securities at December 31, 2019. The cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security at September 30, 2020 consisted of the following September 30, 2020 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value U.S. treasury securities $ 124,608 $ — $ (29 ) $ 124,579 Total $ 124,608 $ — $ (29 ) $ 124,579 The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. At September 30, 2020, there were 13 securities in unrealized loss positions. These securities have not been in a continuous loss position for more than 12 months. Further, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature. None of the Company’s available-for-sale marketable securities had maturities of greater than 12 months at September 30, 2020.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of the Company’s interest receivable, included in prepaid expenses and other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short term nature of these instruments. The Company’s investments, which may include money market funds and available-for-sale investment securities consisting of U.S. treasury securities, and high-quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. Following are the major categories of assets measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands): Fair Value Measurement at End of Period Using: Fair Value Quoted Market Price for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total At September 30, 2020 Money market funds (1) $ 62,031 $ 62,031 $ — $ — $ 62,031 U.S. treasury securities 124,579 124,579 — — 124,579 Total $ 186,610 $ 186,610 $ — $ — 186,610 At December 31, 2019 Money market funds (1) $ 88,159 $ 88,159 $ — $ — $ 88,159 (1) No transfers between

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2020
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	8. Convertible Preferred Stock Prior to its conversion to common stock in connection with the Company’s IPO in April 2020, the Company’s convertible preferred stock was classified as temporary equity on the Company’s balance sheets in accordance with authoritative guidance. Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts): As of December 31, 2019 Shares Authorized Shares Issued and Outstanding Issue Period Issue Price per Share Dividend Annual Rate per Share Aggregate Liquidation Preference Series A 3,862,500 3,862,500 2014 - 2015 $ 4.00 $ 0.32 $ 15,450 Series B 6,750,000 6,749,999 2015 - 2016 $ 8.00 $ 0.64 $ 54,000 Series C 4,448,788 4,448,780 2018 - 2019 $ 12.00 $ 0.96 $ 53,385 Series D 5,287,500 4,217,327 2019 $ 13.20 $ 1.056 $ 55,669 Total 20,348,788 19,278,606 In connection with the Company’s IPO in April 2020, all outstanding shares of the convertible preferred stock converted into 19,278,606 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were no shares of convertible preferred stock outstanding as of the closing of the IPO.

Equity Incentive Plans and Stoc

Equity Incentive Plans and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans and Stock-Based Compensation	9. Equity Incentive Plans and Stock-Based Compensation Equity Incentive Plans In February 2020, the Company’s Board of Directors adopted, and its stockholders approved, the 2020 Equity Incentive Plan (the 2020 Plan), which became effective in April 2020 in connection with the Company’s IPO. Upon adoption of the 2020 Plan, the Company restricted the grant of future equity awards under its 2014 Equity Incentive Plan, as amended and restated (the 2014 Plan). The 2020 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. A total of Stock options granted under the 2020 Plan and the 2014 Plan become exercisable at various dates as determined by the Company’s Board of Directors or its authorized committee and will expire no more than ten years from their date of grant. Stock options generally vest over a four-year As of September 30, 2020, there were 1,514,840 shares available for future issuance under the 2020 Plan. As of December 31, 2019, there were 203,696 shares available for future issuance under the 2014 Plan. The following table summarizes the option activity for the nine months ended September 30, 2020: Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2019 2,683,441 $ 3.75 Granted 1,449,509 16.90 Exercised (69,102 ) 1.62 Forfeited and cancelled (104,155 ) 7.39 Outstanding at September 30 3,959,693 $ 8.52 8.7 $ 65,531 Exercisable at September 30 1,060,901 $ 2.60 8.0 $ 23,797 Certain stock options granted under the Company’s 2014 Plan provided option holders the ability to early exercise their stock options prior to vesting. The shares of common stock granted from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding or issued until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. As of September 30, 2020 and December 31, 2019, there were 7,821 shares and 29,579 shares subject to repurchase by the Company, respectively. As of September 30, 2020 and December 31, 2019, the Company recorded less than $0.1 million of liabilities associated with shares issued with repurchase rights. Employee Stock Purchase Plan In February 2020, the Company’s Board of Directors adopted, and its stockholders approved, the 2020 Employee Stock Purchase Plan (ESPP). The ESPP became effective in connection with the Company’s IPO however no offering period or purchase period under the ESPP will begin unless and until otherwise determined by the Company’s Board of Directors. A total of 290,000 shares of common stock were reserved for future issuance under the ESPP. Further, the number of shares of common stock available for issuance under the ESPP will automatically increase on the first day of each fiscal year following the fiscal year in which the first offering period under the ESPP commences in an amount equal to the lessor of (1) 500,000 shares, (2) 1% of the outstanding shares of the Company’s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company’s Board of Directors. As of September 30, 2020, no shares had been issued pursuant to the ESPP and there were no active offering periods or purchase periods. Stock-Based Compensation Expense Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company’s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the ratable straight-line method over the vesting period. Forfeitures are recognized as they occur. The Company determines the assumptions used in the option pricing model in the following manner: • Expected term. T he expected term represents the period of time that options are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period. • Expected volatility . Due to the Company’s limited historical stock price volatility data, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available . • Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards. • Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero . Prior to the Company’s IPO, the fair value of the Company’s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company’s common stock and the general and industry-specific economic outlook. Subsequent to the Company’s IPO, the fair value of the Company’s common stock is determined based on its closing market price. The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following weighted-average assumptions. Nine Months Ended September 30, 2020 2019 Stock price $16.00 - $35.92 $1.60 - $6.44 Risk-free interest rate 3.17% - 4.45% 1.39% - 2.58% Expected volatility 88.01% - 95.11% 100.52% - 104.15% Expected term (in years) 5.50 - 6.08 6.08 Expected dividend yield 0% 0% The Company recognized stock-based compensation expense of $1.7 million and $0.3 The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Research and development $ 592 $ 116 $ 1,406 $ 233 General and administrative 1,089 155 2,183 419 Total stock-based compensation expense $ 1,681 $ 271 $ 3,589 $ 652

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Operating Leases Rent expense is recorded on a straight-line basis over the term of the respective lease. Total rent expense for the South San Francisco and San Diego locations was $0.3 nine months September 30 Future minimum lease payments under non-cancelable operating leases as of September 30 Operating Leases 2020 remaining three months $ 478 2021 1,871 2022 686 Total minimum lease payments $ 3,035 Litigation From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events On October 19, 2020, the Company entered into the Voronoi License Agreement with Voronoi. The Voronoi License Agreement gives the Company access to Voronoi’s preclinical stage epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutation program, including a lead product candidate now designated as ORIC-114. Under the Voronoi License Agreement, Voronoi granted the Company an exclusive, sublicensable license under Voronoi’s rights to certain patents and patent applications directed to certain small molecule compounds that bind to EGFR and HER2 with one or more exon 20 insertion mutations and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound worldwide (other than in the People’s Republic of China, Hong Kong, Macau and Taiwan) (the ORIC Territory). Under the Voronoi License Agreement, the Company is wholly responsible for development and commercialization of licensed products in the ORIC Territory. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in certain major markets in the ORIC Territory. The Company’s financial obligations under the Voronoi License Agreement included an upfront payment comprised of a $5.0 million cash payment and the issuance to Voronoi of 283,259 shares of the Company’s common stock issued pursuant to a stock issuance agreement (Stock Agreement) entered into between the parties on October 19, 2020. The number of shares issued pursuant to the Stock Agreement was based on a price of $28.24 per share, representing a premium of 25% to the 30-day trailing volume weighted average trading price of the Company’s common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering. The Company is also obligated to make milestone payments to Voronoi upon the achievement of certain events. Upon the achievement of certain development and regulatory milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $111.0 million. Upon the achievement of certain commercial milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $225.0 million. If the Company pursues a second licensed product, the Company would pay Voronoi up to an additional $272.0 million in success-based milestones. In addition, the Company is obligated to pay royalties on net sales of licensed products in the ORIC Territory. Unless earlier terminated, the Voronoi License Agreement will continue in effect until the expiration of all royalty payment obligations. Following the expiration of the Voronoi License Agreement, the Company will retain its licenses under the intellectual property Voronoi licensed to it on a royalty-free basis. The Company and Voronoi may each terminate the Voronoi License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Voronoi may also terminate the agreement if the Company discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Voronoi License Agreement without cause by providing prior notice to Voronoi. If Voronoi terminates the Voronoi License Agreement for cause, or if the Company terminates the Voronoi License Agreement without cause, then the Company is obligated to grant a nonexclusive license to Voronoi under certain of the Company’s patents and know-how and to assign to Voronoi certain of its regulatory filings for licensed compounds and licensed products.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP, have been omitted. The accompanying unaudited financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, the majority of the Company’s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company’s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on April 24 , 2020 under the Securities Act of 1933, as amended (the Securities Act). In the third quarter of 2020, the Company began reporting deferred offering costs within its other assets on its balance sheets. To conform to current presentation, the Company included $1.3 million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company’s total assets, net loss or stockholders’ equity (deficit) as previously reported.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure. The carrying amounts of cash, cash equivalents and marketable securities, prepaid expenses, accounts payable and accrued other liabilities are reasonable estimates of their fair value because of the short maturity of these items.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of 90 days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper.
Marketable Securities	Marketable Securities Investments with maturities at the date of acquisition of more than 90 days are considered marketable securities. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management’s strategies. The Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. Marketable
Research and Development Expenses and Accrued Research and Development Expenses	Research and Development Expenses and Accrued Research and Development Expenses The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified.
License Fees	License Fees Acquisitions of technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator Net loss $ (25,548 ) $ (6,549 ) $ (45,444 ) $ (18,529 ) Denominator Weighted average shares outstanding used in computing net loss per share, basic and diluted 30,314,904 1,946,439 18,022,068 1,876,687 Net loss per share, basic and diluted $ (0.84 ) $ (3.36 ) $ (2.52 ) $ (9.87 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of September 30, 2020 2019 Options to purchase common stock 3,959,693 2,251,594 Convertible preferred stock — 19,278,606 Total 3,959,693 21,530,200
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. In December 2019, the FASB issued ASU No 2019-12 , Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 which had no material effect on the Company’s current financial position, results of operations or financial statement disclosures. New Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Codification Improvements to Topic 842, Leases Leases (Topic 842): Targeted Improvements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses ( Topic 326 ) (ASC 326): Measurement of Credit Losses on Financial Instruments , which introduced the expected credit losses methodology for the

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator Net loss $ (25,548 ) $ (6,549 ) $ (45,444 ) $ (18,529 ) Denominator Weighted average shares outstanding used in computing net loss per share, basic and diluted 30,314,904 1,946,439 18,022,068 1,876,687 Net loss per share, basic and diluted $ (0.84 ) $ (3.36 ) $ (2.52 ) $ (9.87 )
Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of September 30, 2020 2019 Options to purchase common stock 3,959,693 2,251,594 Convertible preferred stock — 19,278,606 Total 3,959,693 21,530,200

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Lab equipment $ 4,088 $ 3,748 Leasehold improvements 1,710 1,710 Computer hardware and software 206 158 Furniture and fixtures 140 140 Total property and equipment, gross 6,144 5,756 Less accumulated depreciation (4,251 ) (3,515 ) Total property and equipment, net $ 1,893 $ 2,241

Accrued Other Liabilities (Tabl

Accrued Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Accrued Liabilities Current [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrued compensation $ 2,229 $ 1,883 Accrued clinical development costs 1,391 484 Accrued professional fees 657 338 Deferred rent - short-term 535 495 Accrued manufacturing costs 278 479 Other accruals 240 279 Accrued deferred financing costs — 1,244 Total accrued liabilities $ 5,330 $ 5,202

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments	The cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security at September 30, 2020 consisted of the following September 30, 2020 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value U.S. treasury securities $ 124,608 $ — $ (29 ) $ 124,579 Total $ 124,608 $ — $ (29 ) $ 124,579

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	Following are the major categories of assets measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands): Fair Value Measurement at End of Period Using: Fair Value Quoted Market Price for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total At September 30, 2020 Money market funds (1) $ 62,031 $ 62,031 $ — $ — $ 62,031 U.S. treasury securities 124,579 124,579 — — 124,579 Total $ 186,610 $ 186,610 $ — $ — 186,610 At December 31, 2019 Money market funds (1) $ 88,159 $ 88,159 $ — $ — $ 88,159 (1)

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2020
Temporary Equity Disclosure [Abstract]
Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms	Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts): As of December 31, 2019 Shares Authorized Shares Issued and Outstanding Issue Period Issue Price per Share Dividend Annual Rate per Share Aggregate Liquidation Preference Series A 3,862,500 3,862,500 2014 - 2015 $ 4.00 $ 0.32 $ 15,450 Series B 6,750,000 6,749,999 2015 - 2016 $ 8.00 $ 0.64 $ 54,000 Series C 4,448,788 4,448,780 2018 - 2019 $ 12.00 $ 0.96 $ 53,385 Series D 5,287,500 4,217,327 2019 $ 13.20 $ 1.056 $ 55,669 Total 20,348,788 19,278,606

Equity Incentive Plans and St_2

Equity Incentive Plans and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Option Activity	The following table summarizes the option activity for the nine months ended September 30, 2020: Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2019 2,683,441 $ 3.75 Granted 1,449,509 16.90 Exercised (69,102 ) 1.62 Forfeited and cancelled (104,155 ) 7.39 Outstanding at September 30 3,959,693 $ 8.52 8.7 $ 65,531 Exercisable at September 30 1,060,901 $ 2.60 8.0 $ 23,797
Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions	The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following weighted-average assumptions. Nine Months Ended September 30, 2020 2019 Stock price $16.00 - $35.92 $1.60 - $6.44 Risk-free interest rate 3.17% - 4.45% 1.39% - 2.58% Expected volatility 88.01% - 95.11% 100.52% - 104.15% Expected term (in years) 5.50 - 6.08 6.08 Expected dividend yield 0% 0%
Summary of Total Stock-based Compensation Expense	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Research and development $ 592 $ 116 $ 1,406 $ 233 General and administrative 1,089 155 2,183 419 Total stock-based compensation expense $ 1,681 $ 271 $ 3,589 $ 652

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Future Minimum Lease Payments under Non-cancelable Operating Leases	Future minimum lease payments under non-cancelable operating leases as of September 30 Operating Leases 2020 remaining three months $ 478 2021 1,871 2022 686 Total minimum lease payments $ 3,035

Description of the Business - A

Description of the Business - Additional Information (Detail) $ / shares in Units, $ in Thousands	Apr. 28, 2020USD ($)$ / sharesshares	Apr. 21, 2020	Jun. 30, 2020shares	Sep. 30, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)	Sep. 30, 2019$ / shares
Description Of Business [Line Items]
Accumulated deficit				$ 138,134	$ 92,690
Gross proceeds from IPO excluding underwriting discounts and commissions and other offering expenses				$ 138,000
Maximum
Description Of Business [Line Items]
Price per share of common stock | $ / shares				$ 35.92		$ 6.44
Minimum
Description Of Business [Line Items]
Price per share of common stock | $ / shares				$ 16		$ 1.60
Common Stock
Description Of Business [Line Items]
Gross proceeds from IPO excluding underwriting discounts and commissions and other offering expenses	$ 138,000
Underwriting discounts and commissions and other offering expenses	12,800
Net proceeds from IPO	$ 125,200
Reverse stock split		one-for-four
Reverse stock split ratio		0.25
Common Stock | Initial Public Offering
Description Of Business [Line Items]
Shares of common stock issued | shares	8,625,000		8,625,000
Price per share of common stock | $ / shares	$ 16
Convertible preferred stock outstanding converted into shares of common stock | shares	19,278,606
Common Stock | Option to Purchase Additional Shares | Maximum
Description Of Business [Line Items]
Shares of common stock issued | shares	1,125,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Liquid investments maturity period	90 days
ASU No 2019-12
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, early adoption	true
Change in accounting principle, accounting standards update, immaterial effect	true
Other Assets
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Deferred offering costs		$ 1.3

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator
Net loss	$ (25,548)	$ (6,549)	$ (45,444)	$ (18,529)
Denominator
Weighted average shares outstanding used in computing net loss per share, basic and diluted	30,314,904	1,946,439	18,022,068	1,876,687
Net loss per share, basic and diluted	$ (0.84)	$ (3.36)	$ (2.52)	$ (9.87)

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti dilutive securities excluded from computation of net loss per share	3,959,693	21,530,200
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti dilutive securities excluded from computation of net loss per share	3,959,693	2,251,594
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti dilutive securities excluded from computation of net loss per share		19,278,606

License Agreements - Additional

License Agreements - Additional Information (Details) $ / shares in Units, $ in Thousands	Aug. 03, 2020USD ($)Product$ / sharesshares	Sep. 30, 2020USD ($)shares	Dec. 31, 2019shares
License Agreements [Line Items]
Number of licensed products obliged to develop and commercialize | Product	1
Upfront payment shares issued | shares		30,545,165	1,984,222
Upfront payment value | $		$ 3
Mirati Therapeutics, Inc
License Agreements [Line Items]
Number of period the agreement in effect	10 years
Mirati Therapeutics, Inc | Private Placement | Common Stock
License Agreements [Line Items]
Upfront payment shares issued | shares	588,235
Upfront payment value | $	$ 13,000
Issue price per share | $ / shares	$ 34
Premium percentage	10.00%
Stock transfer restrictions period	18 months

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 6,144	$ 5,756
Less accumulated depreciation	(4,251)	(3,515)
Total property and equipment, net	1,893	2,241
Lab Equipment
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	4,088	3,748
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,710	1,710
Computer Hardware and Software
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	206	158
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 140	$ 140

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Accrued compensation	$ 2,229	$ 1,883
Accrued clinical development costs	1,391	484
Accrued professional fees	657	338
Deferred rent - short-term	535	495
Accrued manufacturing costs	278	479
Other accruals	240	279
Accrued deferred financing costs		1,244
Total accrued liabilities	$ 5,330	$ 5,202

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	Sep. 30, 2020Security	Dec. 31, 2019USD ($)
Investments Debt And Equity Securities [Abstract]
Marketable securities | $		$ 0
Number of securities in unrealized loss position | Security	13

Marketable Securities - Schedul

Marketable Securities - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details) $ in Thousands	Sep. 30, 2020USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 124,608
Unrealized Losses	(29)
Estimated Fair Value	124,579
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	124,608
Unrealized Losses	(29)
Estimated Fair Value	$ 124,579

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	$ 186,610
Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	62,031	$ 88,159
U.S. Treasury Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	124,579
Level 1
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	186,610
Level 1 | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	62,031	88,159
Level 1 | U.S. Treasury Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	124,579
Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	186,610
Fair Value | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	62,031	$ 88,159
Fair Value | U.S. Treasury Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets, Fair Value	$ 124,579

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Transfer between level 1 to 2	$ 0	$ 0
Transfer between level 2 to 1	0	0
Transfer between level 2 to 3	0	0
Transfer between level 3 to 2	0	0
Transfer between level 1 to 3	0	0
Transfer between level 3 to 1	$ 0	$ 0

Convertible Preferred Stock - S

Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Apr. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Temporary Equity [Line Items]
Shares Authorized	20,348,788
Shares Issued	19,278,606
Shares Outstanding	19,278,606		0
Series A Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	3,862,500	0
Shares Issued	3,862,500	0
Shares Outstanding	3,862,500	0		3,862,500	3,862,500	3,862,500	3,862,500	3,862,500
Issue Price per Share	$ 4
Dividend Annual Rate per Share	$ 0.32
Aggregate Liquidation Preference	$ 15,450	$ 0
Series A Convertible Preferred Stock | Minimum
Temporary Equity [Line Items]
Issue Period	2014
Series A Convertible Preferred Stock | Maximum
Temporary Equity [Line Items]
Issue Period	2015
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	6,750,000	0
Shares Issued	6,749,999
Shares Outstanding	6,749,999	0		6,749,999	6,749,999	6,749,999	6,749,999	6,749,999
Issue Price per Share	$ 8
Dividend Annual Rate per Share	$ 0.64
Aggregate Liquidation Preference	$ 54,000	$ 0
Series B Convertible Preferred Stock | Minimum
Temporary Equity [Line Items]
Issue Period	2015
Series B Convertible Preferred Stock | Maximum
Temporary Equity [Line Items]
Issue Period	2016
Series C Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	4,448,788	0
Shares Issued	4,448,780
Shares Outstanding	4,448,780	0		4,448,780	4,448,780	4,448,780	4,448,780	3,177,271
Issue Price per Share	$ 12
Dividend Annual Rate per Share	$ 0.96
Aggregate Liquidation Preference	$ 53,385	$ 0
Series C Convertible Preferred Stock | Minimum
Temporary Equity [Line Items]
Issue Period	2018
Series C Convertible Preferred Stock | Maximum
Temporary Equity [Line Items]
Issue Period	2019
Series D Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	5,287,500	0
Shares Issued	4,217,327
Shares Outstanding	4,217,327	0		4,217,327	4,217,327	3,777,564
Issue Period	2019
Issue Price per Share	$ 13.20
Dividend Annual Rate per Share	$ 1.056
Aggregate Liquidation Preference	$ 55,669	$ 0

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - shares	Apr. 30, 2020	Dec. 31, 2019
Temporary Equity Disclosure [Abstract]
Outstanding shares of convertible preferred stock converted into shares of common stock	19,278,606
Convertible preferred stock, outstanding	0	19,278,606

Equity Incentive Plans and St_3

Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2020	Oct. 31, 2014	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares subject to repurchase			7,821		7,821		29,579
Expected dividend yield					0.00%	0.00%
Stock-based compensation expense			$ 1,681,000	$ 271,000	$ 3,589,000	$ 652,000
Total unrecognized compensation expense related to outstanding unvested stock-based awards			20,400,000	$ 5,500,000	$ 20,400,000	$ 5,500,000
Total unrecognized compensation expense related to outstanding unvested stock-based awards expected to be recognized over weighted-average remaining service period					2 years 10 months 28 days	3 years 1 month 28 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Liabilities with shares issued with repurchase rights			$ 100,000		$ 100,000		$ 100,000
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock initially reserved for issuance	2,656,500
Additional number of shares available for future issuance	2,656,500
Percentage of outstanding shares of common stock	5.00%
Number of shares available for future issuance			1,514,840		1,514,840
2014 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock remained available for issuance	241,653
Number of shares available for future issuance							203,696
2020 Plan and 2014 Plan | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
2020 Plan and 2014 Plan | Stock Options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period		10 years
2020 Plan and 2014 Plan | Incentive Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price as a percentage of fair market value		100.00%
Minimum percentage required for holders of combined voting power to be eligible for incentive stock options		10.00%
Percentage of options may not be granted at less than fair market value of the common stock at the date of grant		110.00%
Maximum term of options may not be granted at less than fair market value of the common stock at the date of grant		5 years
2020 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional number of shares available for future issuance	500,000
Percentage of outstanding shares of common stock	1.00%
Number of shares available for future issuance	290,000
Number of shares issued under ESPP					0

Equity Incentive Plans and St_4

Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning Balance | shares	2,683,441
Options, Granted | shares	1,449,509
Options, Exercised | shares	(69,102)
Options, Forfeited and cancelled | shares	(104,155)
Options outstanding, Ending Balance | shares	3,959,693
Options, Exercisable | shares	1,060,901
Weighted Average Exercise Price, Options outstanding Beginning Balance | $ / shares	$ 3.75
Weighted Average Exercise Price, Granted | $ / shares	16.90
Weighted Average Exercise Price, Exercised | $ / shares	1.62
Weighted Average Exercise Price, Forfeited and Cancelled | $ / shares	7.39
Weighted Average Exercise Price, Options outstanding Ending Balance | $ / shares	8.52
Weighted Average Exercise Price, Exercisable | $ / shares	$ 2.60
Weighted Average Remaining Contractual Term (in years), Options outstanding	8 years 8 months 12 days
Weighted Average Remaining Contractual Term (in years), Exercisable	8 years
Aggregate Intrinsic Value, Options outstanding | $	$ 65,531
Aggregate Intrinsic Value, Exercisable | $	$ 23,797

Equity Incentive Plans and St_5

Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	3.17%	1.39%
Risk-free interest rate, maximum	4.45%	2.58%
Expected volatility, minimum	88.01%	100.52%
Expected volatility, maximum	95.11%	104.15%
Expected term (in years)		6 years 29 days
Expected dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 16	$ 1.60
Expected term (in years)	5 years 6 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 35.92	$ 6.44
Expected term (in years)	6 years 29 days

Equity Incentive Plans and St_6

Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,681	$ 271	$ 3,589	$ 652
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	592	116	1,406	233
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,089	$ 155	$ 2,183	$ 419

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
South San Francisco and San Diego Locations
Loss Contingencies [Line Items]
Total rent expense	$ 0.3	$ 0.3	$ 1	$ 1

Commitment and Contingencies _2

Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
2020 remaining three months	$ 478
2021	1,871
2022	686
Total minimum lease payments	$ 3,035

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Oct. 19, 2020USD ($)Product$ / sharesshares	Sep. 30, 2020shares	Aug. 03, 2020Product	Dec. 31, 2019shares
Subsequent Event [Line Items]
Number of licensed products obliged to develop and commercialize | Product			1
Upfront payment shares issued | shares		30,545,165		1,984,222
Subsequent Event
Subsequent Event [Line Items]
Number of licensed products obliged to develop and commercialize | Product	1
Subsequent Event | Voronoi Inc. | Development and Regulatory Milestone
Subsequent Event [Line Items]
License agreement, milestone payments maximum amount	$ 111,000,000
Subsequent Event | Voronoi Inc. | Commercial Milestone
Subsequent Event [Line Items]
License agreement, milestone payments maximum amount	225,000,000
Subsequent Event | Voronoi Inc. | Success Based Milestones
Subsequent Event [Line Items]
License agreement, additional milestone payment	272,000,000
Subsequent Event | Private Placement | Voronoi Inc. | Common Stock
Subsequent Event [Line Items]
Upfront cash payment	$ 5,000,000
Upfront payment shares issued | shares	283,259
Issue price per share | $ / shares	$ 28.24
Premium percentage	25.00%